Sandoz Receives FDA Approval for Biosimilar HyrimozTM

October 31, 2018 Scipreneur Private Limited 0

Sandoz Receives FDA Approval for Biosimilar HyrimozTM By: Novartis News Sandoz, a Novartis division and the pioneer and global leader in biosimilars, today announced that the US Food and Drug Administration (FDA) approved its biosimilar, HyrimozTM (adalimumab-adaz). The FDA granted approval for the treatment of rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA) in patients [..]